ArticleJournal of the National Cancer Center2022
Incidence and mortality of cervical cancer in China in 2015.
Article in Journal of the National Cancer Center, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.Human vaccines & immunotherapeutics · 2026Article
- Assessment of Factors and Trends Affecting Different Pathological Types of Cervical Cancer in China From 2013 to 2022.Cancer medicine · 2026Article
- Burden and predictors of cervical cancer mortality in Sub-Saharan Africa: a systematic review and meta-analysis.Infectious agents and cancer · 2026Review
- Associations between vaginal microecological status and high-risk human papillomavirus positivity in women from Eastern China: a retrospective cross-sectional study.Frontiers in medicine · 2026Article
- Age-specific clinical performance of HPV-based vs. cytology-based cervical cancer screening in China.Nature communications · 2025Article
- Impact of government-organized screening programs on the economic burden of cervical cancer across five disease courses: a multistage regression and mediation analysis.Cancer biology & medicine · 2025Article
- HPV transmission and optimal control of cervical cancer in China.Scientific reports · 2025Article
- Divergent trends in the burden of esophageal, gastric, and liver cancers in China.Journal of the National Cancer Center · 2025Article
- HPV vaccination willingness and behavior among patients with cervical intraepithelial neoplasia in low-resource areas of Western China: a cross-sectional study.Frontiers in public health · 2025Article
- Epidemiological characteristics and risk factors of high-risk HPV infection, cervical cancer, and precancerous lesions among women in Southwestern China.Frontiers in oncology · 2025Article
- Enhanced recovery after surgery in the perioperative period promotes recovery of cervical cancer patients undergoing transabdominal radical resection.American journal of translational research · 2025Article
- Research progress of artificial intelligence in the early screening, diagnosis, precise treatment and prognosis prediction of three central gynecological malignancies.Frontiers in oncology · 2025Review
- Population-Level Distribution, Risk Factors, and Burden of Mortality and Disability-Adjusted Life Years Attributable to Major Noncommunicable Diseases in Western Europe (1990-2021): Ecological Analysis.JMIR public health and surveillance · 2024Article
- How can China achieve WHO's 2030 targets for eliminating cervical cancer?BMJ (Clinical research ed.) · 2024Article
- Cervical Cancer Screening via Visual Inspection With Acetic Acid and Lugol Iodine for Triage of HPV-Positive Women.JAMA network open · 2024Article
- Development and validation of aBMC cancer · 2024Article
- Cervical intraepithelial neoplasia and cervical cancer in Hunan Province, China, 2020-2023.Frontiers in oncology · 2024Article
- Exploring the sources of cervical cancer screening self-efficacy among rural females: A qualitative study.Health expectations : an international journal of public participation in health care and health policy · 2023Article
- Substance P is overexpressed in cervical squamous cell carcinoma and promoted proliferation and invasion of cervical cancer cells <em>in vitro</em>.European journal of histochemistry : EJH · 2023Article
- Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation.The oncologist · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To estimate the incidence and mortality of cervical cancer in China based on the cancer registration data in 2015, collected by the National Central Cancer Registry (NCCR). Methods: There were 501 cancer registries that submitted data to the NCCR, whose data were the basis for estimating the incidence and mortality of cervical cancer in China in 2015. After evaluating the data quality, 368 registries' data were accepted for the analysis and stratified by area (urban/rural) and age group. Combined with data on the national population in 2015, the nationwide incidence and mortality of cervical cancer were estimated. Cervical Cancer cases of 22 cancer registries were applied for temporal trends from 2000 to 2015. The Chinese population census in 2000 and Segi's population were used to calculate age-standardized incidence and mortality rates. Results: An estimated 111,000 new cases were attributed to cervical cancer in China in 2015, accounting for 6.24% of all female new cancer cases in that year in China. The crude rate (CR) of incidence and age-standardized incidence rates by the China standard population (ASIRC) and by Segi's world standard population (ASIRW) of cervical cancer were 16.56/100,000, 11.78/100,000, and 10.86/100,000, respectively. The cumulative incidence rate from birth to 74 years old was 1.15%, whereas the calculation of incidence rates over the truncated age range of 35-64 years by Segi's world standard population (T-ASIRW) was 27.66/100,000. The estimates of cervical cancer deaths were about 33,800 and 3.94% of all female cancer-related deaths in China in 2015, with a crude mortality rate of 5.04/100,000. The age-standardized mortality rates adjusted by the Chinese standard population (ASMRC) and by world Segi's population (ASMRW) were 3.29/100,000 and 3.15/100,000, respectively, with a cumulative mortality rate (0-74 years old) of 0.35%. Both the incidence and mortality were higher in rural than in urban areas. The age-specific cervical cancer incidence significantly increased with age, particularly after age 25 years, and peaked at 50-54 years old, whereas age-specific mortality increased rapidly after 35 years old, peaking at 80-84 years old. The age-standardized incidence rates increased by about 8.6 (95% CI: 6.9, 10.3) per year during the period of 2000-2015. The age at diagnosis of patients with cervical cancer tended to be younger. In rural areas, the mean age at diagnosis decreased about 3.22 years from 2000 to 2015 ( Conclusions: China has a high burden of cervical cancer and important disparities among different regions. Especially in the middle and western areas and rural areas, cervical cancer is a serious issue in women's health, and prevention strategies need to be enhanced. Prevention and control strategies need to be enhanced and implemented with reference to local status, such as human papillomavirus (HPV) vaccination and screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.